- Resource Type:
- Presentation
48. Induction ALK-Tkis for Stage III Non-Small Cell Lung Cancer Harboring ALK Fusion: A Single-Center Experience With 3-Year Follow-Up
May 6, 2023
Dennis Wigle , Invited Discussant , Mayo Clinic
Chao Zhang , Abstract Presenter , Guangdong Provincial People's Hospital
103rd Annual Meeting, the Los Angeles Convention Center, Los Angeles, CA, USA
Los Angeles Convention Center, 408B
Abstract
Objective
This study aims to evaluate clinical efficacy and safety of induction ALK-TKIs in stage III non-small cell lung cancer (NSCLC) harboring ALK-fusion.
Methods
Consecutive data from single center were retrospectively collected and those who were pathologically confirmed stage IIIA-IIIB treated with induction ALK-TKIs initially were eligible for subsequent analysis. Response assessment, surgical outcome as well as survival were fully reviewed. Longitudinal single-cell RNA sequencing from two patients treated with Alectinib who happened to exhibit polarized pathological response were analyzed.
Results
39 patients treated with either Alectinib or Crizotinib initially were consecutively collected. 29 patients received surgery after induction ALK-TKIs with median treatment duration of 95 days while others received radiotherapy or continued TKIs treatment. Among those who had surgery, all patients had R0 resection without postoperative radiotherapy. Median operative duration, length of stay and intraoperative blood loss was 150mins, 5 days and 40ml, respectively. No significant difference was found between groups. Only two patients suffered grade 2 postoperative complication in regard to Clavien-Dindo score. 10.3% (3/29) patients had conversion to thoracotomy during minimally invasive lobectomy. No 30-day or 90-day mortality was observed. Induction Alectinib showed numerically superior pathological response compared to Crizotinib with both major pathological response (MPR) (9/16, 56.3% vs. 4/13, 30.8%, p=0.26) and complete pathological response (pCR) (6/16, 37.5% vs. 2/13, 15.4%, p=0.24). Upon a median follow-up time of 35.2 months, patients received induction Alectinib had significantly longer PFS (not reach (NR) vs. 17.9 months, p=0.002) and numerically improved OS (NR vs. 62.6, p=0.226) compared to Crizotinib. Longitudinal single-cell RNA sequencing from two patients revealed increased tumor stemness and induced more suppressive immune microenvironment defined as increased PDCD1, TIGIT, and CTLA4 expression in excessive residual tumor while highly inflamed microenvironment defined by high GNLY, CX3CR1 and CD48 expression along with relatively low infiltrating Treg and Tex in resected specimen which achieved pCR.
Conclusions
Induction ALK-TKIs could be clinically feasible in stage III NSCLC without influencing radical surgery. Alectinib as induction setting continues to show superior efficacy and long-term benefit compared to Crizotinib.
Chao Zhang (1), Ben-Yuan Jiang (1), Li-Xu Yan (1), Si-Yang Liu (1), Zhi-Yong Chen (1), Jun-Tao Lin (1), Qiang Nie (1), Yi-Long Wu (1), Wen-zhao Zhong (1), (1) Guangdong Provincial People's Hospital, Guangzhou, Guangdong
Dennis Wigle
Invited Discussant
Dr. Dennis Wigle is a Thoracic Surgeon and Professor of Surgery at Mayo Clinic.
Chao Zhang
Abstract Presenter
Chao Zhang is a thoracic surgeon as well as a PhD student in Guangdong Lung Cancer Institute. His research interests in Lung Cancer are evolution trajectory of onset in lung adenocarcinoma and personalized perioperative treatment including clinical and translational aspects.